1292324-66-3

Usage

Uses

Used in Pharmaceutical Industry:
(R)-4-aminopyrrolidin-2-one hydrochloride is used as a key intermediate for the synthesis of various pharmaceutical drugs. Its chiral nature allows for the development of enantiomerically pure compounds, which can exhibit different biological activities and reduce potential side effects.
Used in Organic Synthesis:
(R)-4-aminopyrrolidin-2-one hydrochloride is used as a reagent in organic synthesis, enabling the formation of a wide range of organic compounds. Its versatility as a building block allows for the creation of various molecules with potential applications in different industries.
Used in Research and Development:
(R)-4-aminopyrrolidin-2-one hydrochloride is used in research and development for the exploration of its potential therapeutic applications. Its chiral properties make it an interesting candidate for the development of new drugs with improved efficacy and reduced side effects.

Upstream product

• 899806-32-7 (S)-4-azidopyrrolidin-2-one 
• 1346773-63-4 [(3R)-5-oxopyrrolidin-3-yl]carbamic acid tert-butyl ester 

Downstream Products

• 1443929-80-3 C₁₁H₁₂N₂O₂S 

Relevant academic research and scientific papers

PYRROLIDINE DERIVATIVES WITH ANTIBACTERIAL PROPERTIES

Provided is a compound of Formula (I) or a salt thereof: Formula (I) wherein R, m, n, R1, R2, Aa-Ac are defined as in the claims and ArI represents a bicyclic heterocyclic group of the following formula: Formula (2) Ar 2 represents a bicyclic heterocyclic group of the formula: [Formula 3] having antibacterial activity.

HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Aminopurine Compounds having the following structure: (I) wherein R1 , R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

Synthesis of (R)-3,4-diaminobutanoic acid by desymmetrization of dimethyl 3-(benzylamino)glutarate through enzymatic ammonolysis

Lipase B from Candida antarctica is shown to be a highly efficient catalyst for the desymmetrization of dimethyl 3-(benzylamino)glutarate (1) through aminolysis and ammonolysis reactions. Using this procedure, enantiopure monoamides are obtained in high yield. The synthetic value of these compounds is demonstrated by the preparation of an enantiopure nonnatural amino acid, i.e. (R)-3,4-diaminobutanoic acid [(+)-12].